| Drug General Information |
| Drug ID |
D05DNW
|
| Drug Name |
B-623
|
| Synonyms |
149732-37-6; B-623
|
| Indication |
Unspecified
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Complement and coagulation cascades
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
|
E2F transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
FGF signaling pathway
|
|
Reactome
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Complement and Coagulation Cascades
|
|
Endochondral Ossification
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Osteopontin Signaling
|
| References |
| REF 1 | Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. |
|---|
